VIPR1

Across TCGA pan-cancer cohorts, VIPR1 RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of VIPR1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where VIPR1 RNA is repressed in tumor relative to normal tissue. In most cancer types VIPR1 is over-expressed in tumor, although a few such as LUAD and THCA show the opposite, repressed pattern.

LUAD, THCA, and COAD are the cancer types where VIPR1 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in VIPR1 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−3.378	<.001	11	view →
THCA	All	IV	−2.067	<.001	11	view →
COAD	Female	III,IV	−1.822	<.001	11	view →
KIRP	Male	II,III,IV	−0.900	<.001	11	view →
LUSC	Female	II,III,IV	−4.185	<.001	9	view →
LIHC	Male	III,IV	−2.615	<.001	8	view →
KIRC	All	II,III,IV	−0.348	<.001	7	view →
BRCA	Female	II,III,IV	−1.118	<.001	6	view →
READ	Male	All	−3.099	.009	4	view →
CHOL	All	All	−1.924	<.001	3	view →
PAAD	All	All	+0.907	.033	2	view →
UCEC	All	All	+0.708	.003	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

VIPR1–LUAD

Open the LUAD breakdown →